Pure Protein holds intellectual property on the manufacture of soluble HLA proteins which are used in a proprietary method of immunogenic epitope discovery and validation. Receptor Logic, Inc. holds IP on a proprietary method for generating T-cell receptor mimics from defined epitopes. Together, these technologies provide the capability to identify novel disease targets, validate “Usual Suspect” targets, and subsequently “drug” those same targets with monoclonal antibodies (T cell receptor (TCRm)) and other immunotherapeutic modalities. Such modalities include antibody drug conjugates and bispecific antibodies, T cell eliciting vaccines, and via T cells expressing a chimeric antigen receptor derived from the TCRm. Moreover, Pure MHC’s TCRm can readily be optimized for use in diagnostics as well as for other pre-clinical development assays.
Pure MHC is set apart by its exceptional personnel. The team has wide-ranging expertise in many areas including biochemistry, immunology, pharmaceutical biotechnology, microbiology, and organic chemistry.
Dr. William Hildebrand
Founder/Chief Scientist-Target Discovery
Dr. Rico Buchli
Director of Research-TCRm Development
Dr. Curtis McMurtrey
Director of Epitope Discovery
Dr. Saghar Kaabinejadian
Director of Immuno Oncology
In The News